Tham khảo Blisibimod

  1. 1 2 3 4 “A-623: BAFF Peptibody for the Treatment of Lupus”. Anthera Pharmaceuticals, Inc. Bản gốc lưu trữ ngày 2 tháng 9 năm 2011. Truy cập ngày 8 tháng 7 năm 2011. 
  2. 1 2 “Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)” (Thông cáo báo chí). Anthera Pharmaceuticals, Inc. Ngày 29 tháng 7 năm 2010. 
  3. ↑ Browning JL (2006). “B cells move to centre stage: novel opportunities for autoimmune disease treatment”. Nature Reviews. Drug Discovery 5 (7): 564–76. PMID 16816838. doi:10.1038/nrd2085. 
  4. ↑ Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W (2008). “Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus”. Arthritis and Rheumatism 58 (8): 2453–9. PMID 18668552. doi:10.1002/art.23678. 
  5. ↑ Cheema GS, Roschke V, Hilbert DM, Stohl W (2001). “Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases”. Arthritis and Rheumatism 44 (6): 1313–9. PMID 11407690. doi:10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S. 
  6. ↑ Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T (2001). “Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus”. Journal of Immunology 166 (1): 6–10. PMID 11123269. doi:10.4049/jimmunol.166.1.6. 
  7. ↑ Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD (2011). “Intrarenal production of B-cell survival factors in human lupus nephritis” (PDF). Modern Pathology 24 (1): 98–107. PMID 20890272. doi:10.1038/modpathol.2010.184. 
  8. ↑ Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E (2005). “BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma”. The Journal of Experimental Medicine 201 (2): 195–200. PMC 2212784. PMID 15642740. doi:10.1084/jem.20041674. 
  9. ↑ Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, Lombardi S, Pitzalis C, Beltrami CA, Curcio F, De Vita S (2008). “Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma”. The Open Rheumatology Journal 2: 38–43. PMC 2577948. PMID 19088870. doi:10.2174/1874312900802010038. 
  10. ↑ Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, De Vita S, Tonutti E (2010). “BLyS and April serum levels in patients with autoimmune thyroid diseases”. Autoimmunity Reviews 9 (3): 165–9. PMID 19647102. doi:10.1016/j.autrev.2009.07.005. 
  11. ↑ Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA (2011). “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial”. Lancet 377 (9767): 721–31. PMID 21296403. doi:10.1016/S0140-6736(10)61354-2. 
  12. ↑ Genovese, M.C.; Bojin, S.; Biagini, M.; Mociran, E.; Cristei, D.; Georgescu, L.; Sloan-Lancaster, J. (tháng 6 năm 2010). “Effects on b cells, safety, and efficacy of LY2127399, a novel anti-BAFF MAB, in patients with active rheumatoid arthritis”. Annals of the Rheumatic Diseases 69 (Suppl3): 69. 
  13. ↑ “Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases.” (Thông cáo báo chí). Anthera Pharmaceuticals, Inc. Ngày 8 tháng 1 năm 2008. 
  14. ↑ Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA (2015). “A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study”. Annals of the Rheumatic Diseases 74 (9): 1667–75. PMID 24748629. doi:10.1136/annrheumdis-2013-205144. 

Tài liệu tham khảo

WikiPedia: Blisibimod http://www.zora.uzh.ch/35309/4/Neusser_et_al_Intra... http://www.abstracts2view.com/eular/view.php?nu=EU... http://investor.anthera.com/releasedetail.cfm?Rele... http://investor.anthera.com/releasedetail.cfm?Rele... http://www.anthera.com/products_a623.asp/ //www.ncbi.nlm.nih.gov/pmc/articles/PMC2212784 //www.ncbi.nlm.nih.gov/pmc/articles/PMC2577948 //www.ncbi.nlm.nih.gov/pubmed/11123269 //www.ncbi.nlm.nih.gov/pubmed/11407690 //www.ncbi.nlm.nih.gov/pubmed/15642740